This paper is in the following e-collection/theme issue:

Adverse Drug Events Detection, Pharmacovigilance and Surveillance (214) Innovations and Technology in Cancer Care (525) Cancer Prognosis Models and Machine Learning (62) Decision Support for Health Professionals (1515) Clinical Information and Decision Making (1890)

Published on in Vol 13 (2025)

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/72994, first published .
Model for Predicting Serious Hematological Adverse Events in Individuals With Ovarian Cancer Receiving Poly (Adenosine Diphosphate Ribose) Polymerase Inhibitor Treatment: Prospective Cohort Study

Model for Predicting Serious Hematological Adverse Events in Individuals With Ovarian Cancer Receiving Poly (Adenosine Diphosphate Ribose) Polymerase Inhibitor Treatment: Prospective Cohort Study

Model for Predicting Serious Hematological Adverse Events in Individuals With Ovarian Cancer Receiving Poly (Adenosine Diphosphate Ribose) Polymerase Inhibitor Treatment: Prospective Cohort Study

Authors of this article:

Xiaotong Lian1 Author Orcid Image ;   Yu Lei2 Author Orcid Image
Article Authors Cited by Tweetations Metrics

Xiaotong Lian   1 , BPharm ;   Yu Lei   2 , PhD

1 Guangxi Medical University, Nanning, China

2 Guangxi Medical University Affiliated Tumor Hospital, Nanning, China

Corresponding Author:

  • Yu Lei, PhD
  • Guangxi Medical University Affiliated Tumor Hospital
  • 71 Hedi Road, Qingxiu District, Guangxi
  • Nanning 530021
  • China
  • Phone: 86 (0771)5778582
  • Email: 1147112852@qq.com